Show simple item record

dc.contributor.authorPolat,M. Fatih
dc.contributor.authorAktas Anil, Derya
dc.contributor.authorOzkemahli,Gizem
dc.contributor.authorTurkmenoglu, Burcin
dc.contributor.authorHepokur,Ceylan
dc.contributor.authorBurmaoglu,Serdar
dc.contributor.authorAlgul,Oztekin
dc.date.accessioned2024-03-07T11:40:39Z
dc.date.available2024-03-07T11:40:39Z
dc.date.issued2023tr
dc.identifier.urihttps://hdl.handle.net/20.500.12418/14927
dc.description.abstractWe designed and synthesized a novel series of trimethoxy chalcones with CF3 or F substituents at various positions of ring B, characterized using IR, NMR spectral data, and elemental analyses, based on the fact that methoxy and fluoro-substituted chalcones are included in the literature as a pharmacophore due to their anticancer activities. All compounds (12-21) were tested for cytotoxicity against A549, HEPG2, MCF7, and normal mouse fibroblasts (L929) using the XTT assay. The most active compound, 13, was also shown to induce MCF7 cell cycle arrest at the G0/G1 phase, indicating that they exert their antitumor potency via MCF7 cell apoptosis. The mechanisms involved in apoptotic cell death induced by compound 13 were also investigated to see if apoptotic proteins such as Bax, Bcl-2, and p53 were involved. In addition, the compounds with the strongest apoptotic effects against human EGFR and VEGFR-2 receptors were studied in silico. Finally, methoxy and fluoro substituted chalcones derivatives have been shown to have potent anticancer properties.tr
dc.rightsinfo:eu-repo/semantics/closedAccesstr
dc.titleNew Fluoro- and Trifluoromethyl-Substituted Trimethoxychalcones as Anticancer Agents: Synthesis, Bioevaluation, and Computational Studiestr
dc.typearticletr
dc.contributor.departmentEczacılık Fakültesitr
dc.relation.publicationcategoryRaportr


Files in this item

This item appears in the following Collection(s)

Show simple item record